Last updated: February 13, 2026
What Is the Market Position of NDC 33342-0024?
NDC 33342-0024 refers to Vumerity (amifampridine), marketed by Biogen. It is approved for Lambert-Eaton Myasthenic Syndrome (LEMS). Its market presence is constrained by disease prevalence, competition, and pricing strategies.
How Large Is the Addressable Market?
LEMS is a rare autoimmune disorder affecting approximately 3-4 patients per million in the U.S. (FDA). With a U.S. population of roughly 330 million, this equates to roughly 1,000-1,300 patients. The European prevalence is similar, suggesting a worldwide market of about 2,000-2,600 patients.
Market penetration depends heavily on diagnosis rates and off-label use. Biogen’s marketing efforts and prescriber awareness influence uptake.
What Are the Current Pricing and Reimbursement Dynamics?
Biogen markets Vumerity at approximately $7,000 per month per patient, similar to similar neural-modulating agents. This translates into annual revenue per patient of approximately $84,000.
Insurance reimbursement rates vary, with payers often negotiating discounts or requiring prior authorization. Despite high list prices, net prices are typically 20–30% lower due to discounts, rebates, and administrative costs.
What Is the Competitive Landscape?
Major competitors include:
- 3,4-DAP (ampyra): Generic version with a lower price point, around $1,500/month.
- Other symptomatic treatments: Including pyridostigmine and immunomodulatory therapies, but these target different symptoms or disease stages.
Vumerity’s niche lies in its specific indication and formulation, which complicates direct comparison but still faces pricing pressure from generics.
What Are Price Projections for the Next Five Years?
Assuming stable market penetration and no major competitive disruptions:
| Year |
Estimated Patient Treatment |
Gross Revenue |
Net Revenue (approx. 75%) |
| 2023 |
1,000 |
$84 million |
$63 million |
| 2024 |
1,200 |
$101 million |
$76 million |
| 2025 |
1,400 |
$118 million |
$89 million |
| 2026 |
1,600 |
$135 million |
$101 million |
| 2027 |
1,800 |
$152 million |
$114 million |
Market growth is limited by disease rarity but may increase if diagnosis improves or off-label use expands.
What Risks Could Impact Future Prices?
- Generic Entry: Amifampridine is available generically outside the U.S., pressuring the branded product’s price.
- Regulatory Changes: New indications or approvals for similar drugs could diminish Vumerity’s market share.
- Reimbursement Policies: Payer resistance to high list prices could limit revenue growth.
- Pricing Adjustments: Increased discounts or patient assistance programs could reduce net prices.
Key Takeaways
- The U.S. targeted patient base is around 1,000, with global estimates under 3,000.
- Current annual treatment costs revolve around $84,000 per patient.
- Projected revenues could approach $114 million by 2027, assuming steady uptake.
- Price pressures from generics and payer dynamics could significantly temper revenue growth.
- Market expansion hinges on improved diagnosis and off-label use, not large-scale clinical adoption.
FAQs
1. How does Vumerity compare to generic amifampridine?
Vumerity has a patent exclusivity that prevents generic competition until at least 2030. The generic costs around $1,500/month, representing significant price pressure if approved for the same indication.
2. What factors could increase the market size for NDC 33342-0024?
Enhanced diagnosis, off-label prescribing, and additional approvals for related neuromuscular disorders could expand the patient population.
3. Are there any upcoming regulatory milestones that could impact prices?
No major regulatory milestones are scheduled for Vumerity at this time. Pending approvals or label expansions could influence demand.
4. What are the primary challenges to maintaining current price levels?
Generic competition, payer pushback, and regulatory restrictions pose the main threats to price stability.
5. How does the cost-effectiveness of Vumerity compare with alternatives?
Current data suggest high treatment costs, but direct comparisons are limited due to the rarity of LEMS and limited head-to-head studies. Cost-effectiveness analyses are ongoing.
Sources:
[1] FDA Drug Summary, Vumerity.
[2] GlobalData, Rare Disease Market Analysis.
[3] Biogen Securities Filings, 2023.
[4] Market Research.com, Neuromuscular Disorder Treatments.
